SCHEMBL21701240

SCHEMBL21701240

N#Cc1ccc(C(=O)N(CC2CC2)c2cccc(C(=O)Cl)c2F)cc1

nearest known ligand 0.41

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
NSD2 O96028 4/20 0.41
MEN1 O00255 1/20 0.40
NPC1 O15118 1/20 0.40
KMT2A Q03164 1/20 0.40
S1PR1 P21453 1/20 0.38
NSD3 Q9BZ95 1/20 0.38
SIGMAR1 Q99720 1/20 0.35
MLYCD O95822 1/20 0.35
CYP11B1 P15538 1/20 0.35
PDK2 Q15119 1/20 0.33
OXTR P30559 1/20 0.33
AVPR1A P37288 1/20 0.33
GPBAR1 Q8TDU6 1/20 0.33
LPAR1 Q92633 2/20 0.33
LPAR5 Q9H1C0 2/20 0.33
HDAC8 Q9BY41 1/20 0.33
SLC6A2 P23975 1/20 0.33
SLC6A4 P31645 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30222070 1.00 NSD2 (0.41) NSD2MEN1NPC1KMT2AS1PR1
SCHEMBL21693648 0.90 MEN1 (0.43) NSD2MEN1NPC1KMT2AS1PR1
SCHEMBL29857502 0.89 NSD2 (0.41) NSD2MEN1NPC1KMT2AS1PR1
SCHEMBL21705018 0.88 S1PR1 (0.43) KMT2AS1PR1SIGMAR1MLYCDGPBAR1
SCHEMBL30222004 0.88 S1PR1 (0.43) KMT2AS1PR1SIGMAR1MLYCDGPBAR1
SCHEMBL24588307 0.87 HCRTR1 (0.35) NSD2S1PR1CYP11B1PDK2OXTR
SCHEMBL29740342 0.87 HCRTR1 (0.35) NSD2S1PR1CYP11B1PDK2OXTR
SCHEMBL21704816 0.87 S1PR1 (0.49) S1PR1OXTRGPBAR1LPAR1LPAR5
SCHEMBL21693657 0.87 NSD2 (0.39) NSD2MEN1NPC1KMT2AS1PR1
SCHEMBL21693611 0.87 S1PR1 (0.39) S1PR1OXTRGPBAR1LPAR1LPAR5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3816150-B1 M-DIAMIDE COMPOUND AND PREPARATION METHOD THEREFOR AND USE THEREOF CAC SHANGHAI INT TRADING CO LTD (CN) 2024-07-24 EP disclosed
US-20230020373-A1 3-N-CYCLOPROPYLMETHYL-2-FLUOROBENZAMIDE COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF CAC NANTONG CHEMICAL CO., LTD (CN) 2023-01-19 US disclosed
US-11540516-B2 M-diamide compound and preparation method therefor and use thereof CAC SHANGHAI INTERNATIONAL TRADING CO., LTD. (CN) 2023-01-03 US disclosed
US-11540516-B2 M-diamide compound and preparation method therefor and use thereof CAC SHANGHAI INTERNATIONAL TRADING CO., LTD. (CN) 2023-01-03 US disclosed
EP-3816150-A1 M-DIAMIDE COMPOUND AND PREPARATION METHOD THEREFOR AND USE THEREOF Cac Shanghai International Trading Co., Ltd. (CN) 2021-05-05 EP disclosed
EP-3816150-A1 M-DIAMIDE COMPOUND AND PREPARATION METHOD THEREFOR AND USE THEREOF Cac Shanghai International Trading Co., Ltd. (CN) 2021-05-05 EP disclosed
WO-2021078293-A1 3-N-CYCLOPROPYLMETHYL-2-FLUOROBENZAMIDE COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF 南通泰禾化工股份有限公司 2021-04-29 WO disclosed
US-20200178525-A1 M-DIAMIDE COMPOUND AND PREPARATION METHOD THEREOF AND USE THEREOF CAC SHANGHAI INTERNATIONAL TRADING CO., LTD. (CN) 2020-06-11 US disclosed
US-20200178525-A1 M-DIAMIDE COMPOUND AND PREPARATION METHOD THEREOF AND USE THEREOF CAC SHANGHAI INTERNATIONAL TRADING CO., LTD. (CN) 2020-06-11 US disclosed
WO-2020030094-A1 PHARMACEUTICAL COMPOSITION COMPRISING META-DIAMIDE COMPOUND AND USE THEREOF 上海泰禾国际贸易有限公司 2020-02-13 WO disclosed
WO-2020030092-A1 PHARMACEUTICAL COMPOSITION CONTAINING M-DIAMIDE COMPOUND AND APPLICATION THEREOF 上海泰禾国际贸易有限公司 2020-02-13 WO disclosed
WO-2020030095-A1 PHARMACEUTICAL COMPOSITION CONTAINING META-DIAMIDE COMPOUND AND USE THEREOF 上海泰禾国际贸易有限公司 2020-02-13 WO disclosed
WO-2020030096-A1 DRUG COMPOSITION CONTAINING M-DIAMIDE COMPOUND AND APPLICATION OF DRUG COMPOSITION 上海泰禾国际贸易有限公司 2020-02-13 WO disclosed
WO-2020030093-A1 PHARMACEUTICAL COMPOSITION CONTAINING M-DIAMIDE COMPOUND AND APPLICATION THEREOF 上海泰禾国际贸易有限公司 2020-02-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11540516-B2 M-diamide compound and preparation method therefor and use thereof DIMT1, DDT, MRM1 NSD2 1694/4885MEN1 99/4885NPC1 2530/4885
US-20200178525-A1 M-DIAMIDE COMPOUND AND PREPARATION METHOD THEREOF AND USE THEREOF DDT, DIMT1, QDPR NSD2 1386/4885MEN1 143/4885NPC1 2353/4885
US-20230020373-A1 3-N-CYCLOPROPYLMETHYL-2-FLUOROBENZAMIDE COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF CYP51A1, DDT, CYP4F11 NSD2 1687/4885MEN1 504/4885NPC1 1956/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.